NeuroVive presents at the Stockholm Corporate Finance Life Science Seminar
Lund, Sweden, 6 March 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) participates in the Stockholm Corporate Finance Life Science Seminar at Operaterassen on 7 March 2018 at 10:45 a.m. CET. The company's CEO Erik Kinnman will present (in Swedish) the recent development and the future of the company.
Stockholm Corporate Finance organizes the capital market day for the tenth consecutive year, offering investors, analysts and the media to meet companies in the Life Science & Healthcare industry. Over the course of two days, an audience of about 400 people will gather to listen to 16 companies present their activities, followed by a question and answer session led by moderator Linda Wikström, freelance journalist.
To attend the seminar, please register using the link below:
The presentation will also be streamed live on the web:
The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on 6 March 2018.
For more information please contact:
Daniel Schale, Director of Communications
+46 (0)46-275 62 21, email@example.com
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).